

Tanta University

Faculty of Medicine

Clinical Oncology Department

25/11/2020

Time allowed: 3 Hours

MD Exam

Clinical Oncology & Nuclear Medicine

Chemotherapy

All Questions should be answered:

- 1- Standard-risk myeloma — definition and protocols of treatment in HCT (hematopoietic cell transplantation) in eligible patients? 60
- 2- Cancer related fatigue, definition; incidence; screening, diagnosis; contributing issues; and treatment (pharmacological treatment and non- pharmacological interventions)? 60
- 3- Prostate Cancer is basically defined as an androgenic disease. However, the natural history is usually showing heterogenous behavior across disease spectrum. Discuss in detail the above-mentioned statement in relation to genomic profiling and molecular events encountered in backstage of disease? 60
- 4- Discuss biology, patho-physiology of the blood-brain barrier and its clinical relevance? 60
- 5- Discuss the concept of biosimilars and how they are gaining confidence to be incorporated into routine cancer management? 60
- 6- Discuss the impact of CTC (circulating tumor cells) on the management of cancer patients? 60

GOOD LUCK